About this FactMed analysis covering adverse side effect reports of ALBUMINAR-25 patients who developed HEPATITIS.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 2 individuals taking ALBUMINAR-25 reported HEPATITIS to the FDA. A total of 49 ALBUMINAR-25 drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between ALBUMINAR-25 and HEPATITIS. In doing so, we compare ALBUMINAR-25 with other drugs that cause HEPATITIS, to help you evaluate whether or not ALBUMINAR-25 causes HEPATITIS. Likewise, this page shows the most highly-reported side effects of ALBUMINAR-25, so you can see if HEPATITIS ranks among ALBUMINAR-25's most well-known side effects.
Summary Statistics
Reports of ALBUMINAR-25 causing HEPATITIS: 2
Reports of any side effect of ALBUMINAR-25 : 49
Percentage of ALBUMINAR-25 patients where HEPATITIS is a reported side effect: 4.0816%

FDA reports of any drug causing HEPATITIS : 10952
Average percentage for all medicated patients where HEPATITIS is reported as a complication: 0.0686%

Physician opinion on ALBUMINAR-25 as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing ALBUMINAR-25:
PRODUCT USED FOR UNKNOWN INDICATION ( 9 patients )
HYPOALBUMINAEMIA ( 6 patients )
CARDIAC FAILURE ( 2 patients )
SURGERY ( 2 patients )
DRUG USE FOR UNKNOWN INDICATION ( 2 patients )
HAEMODYNAMIC INSTABILITY ( 2 patients )
METASTASES TO LYMPH NODES ( 2 patients )
NEPHROTIC SYNDROME ( 2 patients )
RENAL FAILURE ACUTE ( 2 patients )
URINE OUTPUT DECREASED ( 2 patients )
HEPATIC CIRRHOSIS ( 2 patients )
HYPOTENSION ( 2 patients )
MYASTHENIA GRAVIS ( 1 patients )
PLASMAPHERESIS ( 1 patients )
LIVER DISORDER ( 1 patients )
PNEUMONIA ( 1 patients )
ASCITES ( 1 patients )
CENTRAL VENOUS PRESSURE DECREASED ( 1 patients )
GENERALISED OEDEMA ( 1 patients )
LYMPHANGIOMA ( 1 patients )
( 0 patients )
Drugs with high FDA adverse event association with HEPATITIS:

KETEK (635 patients)
ASPIRIN (515 patients)
ACETAMINOPHEN (421 patients)
OMEPRAZOLE (416 patients)
LIPITOR (384 patients)
FOSAMAX (343 patients)
PREDNISONE (338 patients)
PREDNISOLONE (328 patients)
CYMBALTA (322 patients)
REMICADE (315 patients)
METHOTREXATE (296 patients)
VIOXX (290 patients)
ACCUTANE (283 patients)
NEXIUM (271 patients)
HUMIRA (254 patients)
LASIX (249 patients)
SEROQUEL (230 patients)
CRESTOR (229 patients)
AUGMENTIN '125' (223 patients)
FUROSEMIDE (218 patients)
CYCLOPHOSPHAMIDE (215 patients)
ALLOPURINOL (212 patients)
NEURONTIN (211 patients)
SIMVASTATIN (209 patients)
IBUPROFEN (204 patients)
LEVOTHYROXINE SODIUM (190 patients)
ISONIAZID (184 patients)
ZOMETA (184 patients)
AVONEX (178 patients)
XANAX (178 patients)
ZOCOR (177 patients)
PLAVIX (177 patients)
SYNTHROID (175 patients)
DEXAMETHASONE (168 patients)
METFORMIN HCL (161 patients)
TRUVADA (158 patients)
ATENOLOL (157 patients)
PYRAZINAMIDE (154 patients)
PARACETAMOL (154 patients)
EFAVIRENZ (153 patients)
LAMIVUDINE (151 patients)
HYDROCHLOROTHIAZIDE (151 patients)
LYRICA (150 patients)
CELEBREX (149 patients)
FOLIC ACID (148 patients)
PRILOSEC (148 patients)
RISPERDAL (147 patients)
PREDNISONE TAB (146 patients)
LISINOPRIL (146 patients)
MORPHINE (145 patients)
ZOLOFT (143 patients)
PROTONIX (143 patients)
GLUCOPHAGE (142 patients)
ALBUTEROL (139 patients)
PREMARIN (139 patients)
NORVASC (137 patients)
RITONAVIR (135 patients)
COMBIVIR (135 patients)
BACTRIM (135 patients)
COUMADIN (132 patients)
PREVACID (131 patients)
SINGULAIR (129 patients)
AMOXICILLIN (128 patients)
TYLENOL (CAPLET) (128 patients)
WARFARIN SODIUM (123 patients)
REBIF (122 patients)
GABAPENTIN (120 patients)
ENBREL (120 patients)
RIFAMPICIN (120 patients)
DIGOXIN (118 patients)
INSULIN (118 patients)
PROZAC (117 patients)
ZYPREXA (116 patients)
CLONAZEPAM (116 patients)
ATORVASTATIN CALCIUM (116 patients)
AMBIEN (114 patients)
LORAZEPAM (113 patients)
NOROXIN (113 patients)
TRAMADOL HCL (113 patients)
LAMICTAL (112 patients)
TRACLEER (110 patients)
TOPROL-XL (109 patients)
AREDIA (108 patients)
SPIRONOLACTONE (108 patients)
CYCLOSPORINE (108 patients)
ZETIA (107 patients)
METHYLPREDNISOLONE (107 patients)
LEVAQUIN (106 patients)
ZYRTEC (105 patients)
ARAVA (104 patients)
GLEEVEC (104 patients)
DECADRON (104 patients)
AVELOX (104 patients)
NORVIR (104 patients)
SOLU-MEDROL (104 patients)
RAMIPRIL (103 patients)
ALDACTONE (102 patients)
BENADRYL (102 patients)
AMLODIPINE (101 patients)
LANSOPRAZOLE (101 patients)
LEXAPRO (98 patients)
LEVOFLOXACIN (97 patients)
TYLENOL (96 patients)
FLUCONAZOLE (93 patients)
VYTORIN (93 patients)
DIAZEPAM (93 patients)
OXYCONTIN (92 patients)
POTASSIUM CHLORIDE (92 patients)
DIOVAN (91 patients)
CARBAMAZEPINE (91 patients)
KALETRA (88 patients)
JANUVIA (88 patients)
CELEXA (88 patients)
ENALAPRIL MALEATE (88 patients)
RANITIDINE (87 patients)
VANCOMYCIN (87 patients)
CIPROFLOXACIN (87 patients)
EXTRA STRENGTH TYLENOL (86 patients)
AZATHIOPRINE (86 patients)
ETHAMBUTOL HYDROCHLORIDE (85 patients)
MIRTAZAPINE (85 patients)
EXJADE (84 patients)
VICODIN (84 patients)
VINCRISTINE (84 patients)
EFFEXOR (84 patients)
CLOZARIL (84 patients)
REYATAZ (83 patients)
ROCEPHIN (83 patients)
TMC114 (83 patients)
PROPOFOL (83 patients)
METFORMIN (82 patients)
ATIVAN (81 patients)
ZIDOVUDINE (80 patients)
CITALOPRAM HYDROBROMIDE (80 patients)
VITAMIN D (80 patients)
ZITHROMAX (79 patients)
NEVIRAPINE (78 patients)
NEORAL (78 patients)
VOLTAREN (78 patients)
FORTEO (77 patients)
LAMISIL (77 patients)
PANTOPRAZOLE SODIUM (77 patients)
SULFASALAZINE (77 patients)
LANTUS (76 patients)
PERCOCET (76 patients)
VIRAMUNE (76 patients)
TOPAMAX (76 patients)
CALCIUM (76 patients)
BISOPROLOL FUMARATE (75 patients)
FLUOXETINE (73 patients)
MYCOPHENOLATE MOFETIL (73 patients)
VALIUM (73 patients)
TRICOR (73 patients)
OXYCODONE HCL (73 patients)
VIREAD (73 patients)
RISPERIDONE (73 patients)
FLAGYL (72 patients)
TEGRETOL (71 patients)
AMARYL (71 patients)
FAMOTIDINE (71 patients)
ALLEGRA (71 patients)
STRATTERA (71 patients)
ADVAIR DISKUS 100/50 (71 patients)
ACYCLOVIR (70 patients)
CORTANCYL (69 patients)
LACTULOSE (69 patients)
GLIPIZIDE (69 patients)
KEPPRA (69 patients)
ADVIL (69 patients)
METOCLOPRAMIDE (69 patients)
LOVENOX (69 patients)
RIFAMPIN (68 patients)
TYSABRI (68 patients)
MULTI-VITAMINS (68 patients)
METRONIDAZOLE (67 patients)
PAXIL (66 patients)
GLYBURIDE (66 patients)
AVANDIA (66 patients)
COMPAZINE (66 patients)
OLANZAPINE (66 patients)
COREG (66 patients)
NASONEX (65 patients)
METOPROLOL TARTRATE (65 patients)
CELLCEPT (64 patients)
BYETTA (64 patients)
EPIVIR (64 patients)
DILAUDID (64 patients)
AMLODIPINE BESYLATE (64 patients)
DIDANOSINE (63 patients)
FLONASE (62 patients)
CORDARONE (62 patients)
RIVOTRIL (62 patients)
DURAGESIC-100 (62 patients)
TRAZODONE HCL (61 patients)
CLARITHROMYCIN (61 patients)
ACTOS (61 patients)
MABTHERA (60 patients)
AZITHROMYCIN (60 patients)
PREZISTA (59 patients)
ZOFRAN (59 patients)
DICLOFENAC SODIUM (59 patients)
RITUXIMAB (59 patients)
FLUOROURACIL (59 patients)
REVLIMID (59 patients)
ALENDRONATE SODIUM (59 patients)
ADALAT (59 patients)
ALPRAZOLAM (58 patients)
VITAMIN B-12 (58 patients)
AUGMENTIN (58 patients)
TYLENOL-500 (58 patients)
Most common side effects for patients taking ALBUMINAR-25:
BLOOD PRESSURE DECREASED (11 patients)
INFUSION RELATED REACTION (7 patients)
HEPATITIS C POSITIVE (4 patients)
OXYGEN SATURATION DECREASED (4 patients)
HEPATIC FAILURE (3 patients)
HEPATITIS C ANTIBODY POSITIVE (3 patients)
TACHYCARDIA (3 patients)
HEPATITIS C VIRUS TEST POSITIVE (3 patients)
ANTINUCLEAR ANTIBODY POSITIVE (3 patients)
PYREXIA (3 patients)
HYPERSENSITIVITY (3 patients)
CHILLS (3 patients)
BLOOD CULTURE POSITIVE (2 patients)
PLATELET COUNT DECREASED (2 patients)
LOSS OF CONSCIOUSNESS (2 patients)
PRODUCT QUALITY ISSUE (2 patients)
KLEBSIELLA INFECTION (2 patients)
BACTERIAL INFECTION (2 patients)
BODY TEMPERATURE INCREASED (2 patients)
HYPOXIA (2 patients)
HYPOTENSION (2 patients)
PRURITUS (2 patients)
PULMONARY EMBOLISM (2 patients)
RASH (2 patients)
HEPATITIS C RNA POSITIVE (2 patients)
CROHN'S DISEASE (2 patients)
RESTLESSNESS (2 patients)
TRANSMISSION OF AN INFECTIOUS AGENT VIA A MEDICINAL PRODUCT (2 patients)
HEPATITIS B VIRUS TEST POSITIVE (2 patients)
HEPATITIS B POSITIVE (2 patients)
DYSKINESIA (2 patients)
HEPATITIS (2 patients)
HEPATITIS C (2 patients)
HEADACHE (2 patients)
FOAMING AT MOUTH (2 patients)
FLUSHING (2 patients)
FATIGUE (1 patients)
HAEMOGLOBIN DECREASED (1 patients)
HAEMOLYSIS (1 patients)
EYE SWELLING (1 patients)
ENTEROCOLONIC FISTULA (1 patients)
HEPATIC FUNCTION ABNORMAL (1 patients)
DYSPNOEA (1 patients)
HEPATITIS B CORE ANTIGEN POSITIVE (1 patients)
DRUG HYPERSENSITIVITY (1 patients)
HEPATITIS B SURFACE ANTIGEN POSITIVE (1 patients)
DIARRHOEA (1 patients)
ABDOMINAL DISCOMFORT (1 patients)
CYANOSIS (1 patients)
CULTURE URINE POSITIVE (1 patients)
CORONARY ARTERY INSUFFICIENCY (1 patients)
COOMBS DIRECT TEST POSITIVE (1 patients)
COMPLICATIONS OF TRANSPLANTED LIVER (1 patients)
CATHETER SITE HAEMORRHAGE (1 patients)
CARDIO-RESPIRATORY ARREST (1 patients)
BLOOD PRESSURE SYSTOLIC DECREASED (1 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (1 patients)
BLOOD PRESSURE FLUCTUATION (1 patients)
LABORATORY TEST ABNORMAL (1 patients)
LARGE INTESTINE PERFORATION (1 patients)
LIP SWELLING (1 patients)
LIVER TRANSPLANT (1 patients)
BLOOD GLUCOSE INCREASED (1 patients)
NEUTROPHIL COUNT DECREASED (1 patients)
NOSOCOMIAL INFECTION (1 patients)
ORTHOPNOEA (1 patients)
BLOOD FIBRINOGEN DECREASED (1 patients)
PALLOR (1 patients)
BLOOD CREATININE INCREASED (1 patients)
PNEUMONIA KLEBSIELLA (1 patients)
POST PROCEDURAL COMPLICATION (1 patients)
PRODUCT OUTER PACKAGING ISSUE (1 patients)
PRODUCT PACKAGING QUANTITY ISSUE (1 patients)
BLOOD BILIRUBIN INCREASED (1 patients)
PROTHROMBIN TIME PROLONGED (1 patients)
BACK PAIN (1 patients)
ASTHENIA (1 patients)
PULMONARY OEDEMA (1 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (1 patients)
ANAPHYLACTIC SHOCK (1 patients)
RECTAL HAEMORRHAGE (1 patients)
RENAL DISORDER (1 patients)
ANAPHYLACTIC REACTION (1 patients)
RETROPERITONEAL ABSCESS (1 patients)
SEROLOGY POSITIVE (1 patients)
SWELLING FACE (1 patients)
ALANINE AMINOTRANSFERASE INCREASED (1 patients)
ADVERSE EVENT (1 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (1 patients)
URINARY TRACT INFECTION FUNGAL (1 patients)
URINE OUTPUT DECREASED (1 patients)
URTICARIA (1 patients)
VENA CAVA THROMBOSIS (1 patients)
WHITE BLOOD CELL COUNT DECREASED (1 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for ALBUMINAR-25


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about HEPATITIS and ALBUMINAR-25, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking ALBUMINAR-25, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in ALBUMINAR-25. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for ALBUMINAR-25 experts. If you are a healthcare provider experienced in prescribing ALBUMINAR-25, please register here.
giCould not connect: